P450 CYP2C epoxygenase and CYP4A ω-hydroxylase mediate ciprofibrate-induced PPARα-dependent peroxisomal proliferation

Journal of Lipid Research

Volumn 48, Issue 4, 2007, Pages 924-934

  Gatica, Arnaldo ^a   Aguilera, Mauricio C ^a   Contador, David ^a   Loyola, Gloria ^a   Pinto, Claudio O ^a   Amigo, Ludwig ^a   Tichauer, Juan E ^a   Zanlungo, Silvana ^a   Bronfman, Miguel ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

hydroxylated eicosatrienoic acids; P450 monooxygenases; Peroxisome proliferator activated receptor

Indexed keywords

ARACHIDONIC ACID; CIPROFIBRATE; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 4A; HYDROXYLATED EICOSATRIENOIC ACID; ICOSATRIENOIC ACID; OXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GENE IDENTIFICATION; GENE OVEREXPRESSION; LIPID METABOLISM; LIPID OXIDATION; LIPID STORAGE; LIPID TRANSPORT; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; TRANSCRIPTION INITIATION;

ALKANE 1-MONOOXYGENASE; ANIMALS; ARACHIDONIC ACID; CELLS, CULTURED; CLOFIBRIC ACID; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HYDROXYEICOSATETRAENOIC ACIDS; LIGANDS; PEROXISOMES; PPAR ALPHA; RATS;

EID: 34147191450     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700002-JLR200     Document Type: Article

References (69)

1. Desvergne, B., and W. Wahli. 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20: 649-688.
2. Reddy, J. K., and T. Hashimoto. 2001. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 21: 193-230.
3. Lazarow, P. B., and C. De Duve. 1976. A fatty acyl-CoA oxidizing system in rat liver peroxisomes: enhancement by clofibrate, a hypolipidemic drug. Proc. Natl. Acad. Sci. USA. 73: 2043-2046.
4. Reddy, J. K., S. K. Goel, M. R. Nemali, J. J. Carrino, T. G. Laffler, M. K. Reddy, S. J. Sperbeck, T. Osumi, T. Hashimoto, N. D. Lalwani, et al. 1986. Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proc. Natl. Acad. Sci. USA. 83: 1747-1751.
5. Bronfman, M., M. N. Morales, L. Amigo, A. Orellana, L. Nunez, L. Cardenas, and P. C. Hidalgo. 1992. Hypolipidaemic drugs are activated to acyl-CoA esters in isolated rat hepatocytes. Detection of drug activation by human liver homogenates and by human platelets. Biochem. J. 284: 289-295.
6. Hertz, R., V. Sheena, B. Kalderon, I. Berman, and J. Bar-Tana. 2001. Suppression of hepatocyte nuclear factor-4alpha by acyl-CoA thioesters of hypolipidemic peroxisome proliferators. Biochem. Pharmacol. 61: 1057-1062.
7. Voltti, H., M. J. Savolainen, V. P. Jauhonen, and I. E. Hassinen. 1979. Clofibrate-induced increase in coenzyme A concentration in rat tissues. Biochem. J. 182: 95-102.
8. Halvorsen, O. 1983. Effects of hypolipidemic drugs on hepatic CoA. Biochem. Pharmacol. 32: 1126-1128.
9. Reddy, J. K., D. L. Azarnoff, and C. E. Hignite. 1980. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature. 283: 397-398.
10. Lee, S. S., T. Pineau, J. Drago, E. J. Lee, J. W. Owens, D. L. Kroetz, P. M. Fernandez-Salguero, H. Westphal, and F. J. Gonzalez. 1995. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15: 3012-3022.
11. Forman, B. M., J. Chen, and R. M. Evans. 1997. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. USA. 94: 4312-4317.
12. Lin, Q., S. E. Ruuska, N. S. Shaw, D. Dong, and N. Noy. 1999. Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry. 38: 185-190.
13. Murakami, K., T. Ide, M. Suzuki, T. Mochizuki, and T. Kadowaki. 1999. Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferator-activated receptor alpha. Biochem. Biophys. Res. Commun. 260: 609-613.
14. Cowart, L. A., S. Wei, M. H. Hsu, E. F. Johnson, M. U. Krishna, J. R. Falck, and J. H. Capdevila. 2002. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator- activated receptor ligands. J. Biol. Chem. 277: 35105-35112.
15. Capdevila, J. H., R. C. Harris, and J. R. Falck. 2002. Microsomal cytochrome P450 and eicosanoid metabolism. Cell. Mol. Life Sci. 59: 780-789.
16. Capdevila, J. H., and J. R. Falck. 2001. The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem. Biophys. Res. Commun. 285: 571-576.
17. Maier, K. G., and R. J. Roman. 2001. Cytochrome P450 metabolites of arachidonic acid in the control of renal function. Curr. Opin. Nephrol. Hypertens. 10: 81-87.
18. Chen, J. K., D. W. Wang, J. R. Falck, J. Capdevila, and R. C. Harris. 1999. Transfection of an active cytochrome P450 arachidonic acid epoxygenase indicates that 14,15-epoxyeicosatrienoic acid functions as an intracellular second messenger in response to epidermal growth factor. J. Biol. Chem. 274: 4764-4769.
19. Hardwick, J. P., B. J. Song, E. Huberman, and F. J. Gonzalez. 1987. Isolation, complementary DNA sequence, and regulation of rat hepatic lauric acid omega-hydroxylase (cytochrome P-450LA omega). Identification of a new cytochrome P-450 gene family. J. Biol. Chem. 262: 801-810.
20. Helvig, C., E. Dishman, and J. H. Capdevila. 1998. Molecular, enzymatic, and regulatory characterization of rat kidney cytochromes P450 4A2 and 4A3. Biochemistry. 37: 12546-12558.
21. Hoch, U., Z. Zhang, D. L. Kroetz, and P. R. Ortiz de Montellano. 2000. Structural determination of the substrate specificities and regioselectivities of the rat and human fatty acid omega-hydroxylases. Arch. Biochem. Biophys. 373: 63-71.
22. Kroetz, D. L., P. Yook, P. Costet, P. Bianchi, and T. Pineau. 1998. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J. Biol. Chem. 273: 31581-31589.
23. Johnson, E. F., C. N. Palmer, K. J. Griffin, and M. H. Hsu. 1996. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. FASEB J. 10: 1241-1248.
24. Berry, M. N., and D. S. Friend. 1969. High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J. Cell Biol. 43: 506-520.
25. Capdevila, J. H., E. Dishman, A. Karara, and J. R. Falck. 1991. Cytochrome P450 arachidonic acid epoxygenase: stereochemical characterization of epoxyeicosatrienoic acids. Methods Enzymol. 206: 441-453.
26. Capdevila, J., J. Falck, E. Dishman, and A. Karara. 1989. Cytochrome P-450 arachidonate oxygenase. Methods Enzymol. 187: 385-394.
27. Falck, J. R., P. Yadagiri, and J. Capdevila. 1990. Synthesis of epoxyeicosatrienoic acids and heteroatom analogs. Methods Enzymol. 187: 357-364.
28. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate- phenol-chloroform extraction. Anal. Biochem. 162: 156-159.
29. Helvig, C., and J. H. Capdevila. 2000. Biochemical characterization of rat P450 2C11 fused to rat or bacterial NADPH-P450 reductase domains. Biochemistry. 39: 5196-5205.
30. Kozarsky, K. F., K. Jooss, M. Donahee, J. F. Strauss, 3rd, and J. M. Wilson. 1996. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat. Genet. 13: 54-62.
31. Devchand, P. R., H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli. 1996. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 384: 39-43.
32. Keller, H., C. Dreyer, J. Medin, A. Mahfoudi, K. Ozato, and W. Wahli. 1993. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA. 90: 2160-2164.
33. Yu, K., W. Bayona, C. B. Kallen, H. P. Harding, C. P. Ravera, G. McMahon, M. Brown, and M. A. Lazar. 1995. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270: 23975-23983.
34. Kliewer, S. A., S. S. Sundseth, S. A. Jones, P. J. Brown, G. B. Wisely, C. S. Koble, P. Devchand, W. Wahli, T. M. Willson, J. M. Lenhard, et al. 1997. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. USA. 94: 4318-4323.
35. Capdevila, J., L. Gil, M. Orellana, L. J. Marnett, J. I. Mason, P. Yadagiri, and J. R. Falck. 1988. Inhibitors of cytochrome P-450-dependent arachidonic acid metabolism. Arch. Biochem. Biophys. 261: 257-263.
36. Santos, M. J., T. Imanaka, H. Shio, and P. B. Lazarow. 1988. Peroxisomal integral membrane proteins in control and Zellweger fibroblasts. J. Biol. Chem. 263: 10502-10509.
37. Garcia-Allan, C., J. Loughlin, T. Orton, and P. Lord. 1997. Changes in protein and mRNA levels of growth factor/growth factor receptors in rat livers after administration of phenobarbitone or methylclofenapate. Arch. Toxicol. 71: 409-415.
38. Koshihara, Y., T. Neichi, S. Murota, A. Lao, Y. Fujimoto, and T. Tatsuno. 1984. Caffeic acid is a selective inhibitor for leukotriene biosynthesis. Biochim. Biophys. Acta. 792: 92-97.
39. Sekiya, K., and H. Okuda. 1982. Selective inhibition of platelet lipoxygenase by baicalein. Biochem. Biophys. Res. Commun. 105: 1090-1095.
40. Gleason, M. M., C. J. Rojas, K. S. Learn, M. H. Perrone, and G. E. Bilder. 1995. Characterization and inhibition of 15-lipoxygenase in human monocytes: comparison with soybean 15-lipoxygenase. Am. J. Physiol. 268: C1301-C1307.
41. Jaradat, M. S., B. Wongsud, S. Phornchirasilp, S. M. Rangwala, G. Shams, M. Sutton, K. J. Romstedt, D. J. Noonan, and D. R. Feller. 2001. Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem. Pharmacol. 62: 1587-1595.
42. Wang, M. H., E. Brand-Schieber, B. A. Zand, X. Nguyen, J. R. Falck, N. Balu, and M. L. Schwartzman. 1998. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J. Pharmacol. Exp. Ther. 284: 966-973.
43. Corton, J. C., L. Q. Fan, S. Brown, S. P. Anderson, C. Bocos, R. C. Cattley, A. Mode, and J. A. Gustafsson. 1998. Down-regulation of cytochrome P450 2C family members and positive acute-phase response gene expression by peroxisome proliferator chemicals. Mol. Pharmacol. 54: 463-473.
44. Fang, X., T. L. Kaduce, M. VanRollins, N. L. Weintraub, and A. A. Spector. 2000. Conversion of epoxyeicosatrienoic acids (EETs) to chain-shortened epoxy fatty acids by human skin fibroblasts. J. Lipid Res. 41: 66-74.
45. Spector, A. A., X. Fang, G. D. Snyder, and N. L. Weintraub. 2004. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. 43: 55-90.
46. Karara, A., E. Dishman, J. R. Falck, and J. H. Capdevila. 1991. Endogenous epoxyeicosatrienoyl-phospholipids. A novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J. Biol. Chem. 266: 7561-7569.
47. Lee, T. C. 1998. Biosynthesis and possible biological functions of plasmalogens. Biochim. Biophys. Acta. 1394: 129-145.
48. Thai, T. P., C. Rodemer, J. Worsch, A. Hunziker, K. Gorgas, and W. W. Just. 1999. Synthesis of plasmalogens in eye lens epithelial cells. FEBS Lett. 456: 263-268.
49. Fan, C. Y., J. Pan, N. Usuda, A. V. Yeldandi, M. S. Rao, and J. K. Reddy. 1998. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J. Biol. Chem. 273: 15639-15645.
50. Hashimoto, T., T. Fujita, N. Usuda, W. Cook, C. Qi, J. M. Peters, F. J. Gonzalez, A. V. Yeldandi, M. S. Rao, and J. K. Reddy. 1999. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J. Biol. Chem. 274: 19228-19236.
51. Capdevila, J. H., J. R. Falck, and R. C. Harris. 2000. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J. Lipid Res. 41: 163-181.
52. Fang, X., S. Hu, B. Xu, G. Snyder, S. Harmon, J. Yao, Y. Liu, B. Sangras, J. Falck, N. L. Weintraub, and A. A. Spector. 2006. 14,15- Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. Am. J. Physiol. Heart Circ. Physiol. 290: H55-H63.
53. Anderson, N. L., R. Esquer-Blasco, F. Richardson, P. Foxworthy, and P. Eacho. 1996. The effects of peroxisome proliferators on protein abundances in mouse liver. Toxicol. Appl. Pharmacol. 137: 75-89.
54. McGiff, J. C., and J. Quilley. 1999. 20-HETE and the kidney: resolution of old problems and new beginnings. Am. J. Physiol. 277: R607-R623.
55. Hertz, R., and J. Bar-Tana. 1998. Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans. Toxicol. Lett. 102-103: 85-90.
56. Cattley, R. C., J. DeLuca, C. Elcombe, P. Fenner-Crisp, B. G. Lake, D. S. Marsman, T. A. Pastoor, J. A. Popp, D. E. Robinson, B. Schwetz, et al. 1998. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul. Toxicol. Pharmacol. 27: 47-60.
57. Krey, G., O. Braissant, F. L'Horset, E. Kalkhoven, M. Perroud, M. G. Parker, and W. Wahli. 1997. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11: 779-791.
58. Issemann, I., and S. Green. 1991. Cloning of novel members of the steroid hormone receptor superfamily. J. Steroid Biochem. Mol. Biol. 40: 263-269.
59. Bronfman, M., L. Nunez, A. Orellana, V. Burzio, and P. Hidalgo. 1996. Peroxisome proliferators and signal transduction. Ann. N. Y. Acad. Sci. 804: 403-412.
60. Hunt, M. C., S. E. Nousiainen, M. K. Huttunen, K. E. Orii, L. T. Svensson, and S. E. Alexson. 1999. Peroxisome proliferatorinduced long chain acyl-CoA thioesterases comprise a highly conserved novel multi-gene family involved in lipid metabolism. J. Biol. Chem. 274: 34317-34326.
61. Petrescu, A. D., R. Hertz, J. Bar-Tana, F. Schroeder, and A. B. Kier. 2002. Ligand specificity and conformational dependence of the hepatic nuclear factor-4alpha (HNF-4alpha). J. Biol. Chem. 277: 23988-23999.
62. Hertz, R., J. Bishara-Shieban, and J. Bar-Tana. 1995. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J. Biol. Chem. 270: 13470-13475.
63. Mietus-Snyder, M., F. M. Sladek, G. S. Ginsburg, C. F. Kuo, J. A. Ladias, J. E. Darnell, Jr., and S. K. Karathanasis. 1992. Antagonism between apolipoprotein AI regulatory protein 1, Ear3/COUP-TF, and hepatocyte nuclear factor 4 modulates apolipoprotein CIII gene expression in liver and intestinal cells. Mol. Cell. Biol. 12: 1708-1718.
64. Hayhurst, G. P., Y. H. Lee, G. Lambert, J. M. Ward, and F. J. Gonzalez. 2001. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol. Cell. Biol. 21: 1393-1403.
65. Palmer, C. N., M. H. Hsu, K. J. Griffin, J. L. Raucy, and E. F. Johnson. 1998. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol. Pharmacol. 53: 14-22.
66. Yu, S., W. Q. Cao, P. Kashireddy, K. Meyer, Y. Jia, D. E. Hughes, Y. Tan, J. Feng, A. V. Yeldandi, M. S. Rao, et al. 2001. Human peroxisome proliferator-activated receptor alpha (PPARalpha) supports the induction of peroxisome proliferation in PPARalpha-deficient mouse liver. J. Biol. Chem. 276: 42485-42491.
67. Daikh, B. E., J. M. Lasker, J. L. Raucy, and D. R. Koop. 1994. Regio-and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J. Pharmacol. Exp. Ther. 271: 1427-1433.
68. Zeldin, D. C., C. R. Moomaw, N. Jesse, K. B. Tomer, J. Beetham, B. D. Hammock, and S. Wu. 1996. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch. Biochem. Biophys. 330: 87-96.
69. Le Quere, V., E. Plee-Gautier, P. Potin, S. Madec, and J. P. Salaun. 2004. Human CYP4F3s are the main catalysts in the oxidation of fatty acid epoxides. J. Lipid Res. 45: 1446-1458.